KFAS
LAB icon

Keating Financial Advisory Services’s Standard BioTools LAB Stock Holding History

Keating Financial Advisory Services’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-402
Closed -$515 – 2623
2025
Q4 		$515 Buy
+402
New +$540 ﹤0.01% 1944

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Keating Financial Advisory Services's LAB Position: Q1 2026 in Review

Keating Financial Advisory Services sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 402 shares — an estimated $515 sold.

Keating Financial Advisory Services first reported a position in LAB in Q4 2025 and held it in 1 quarter. The position peaked at $515 in Q4 2025. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Keating Financial Advisory Services reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
  • Keating Financial Advisory Services sold 402 Standard BioTools shares in Q1 2026, an estimated $515.
  • Keating Financial Advisory Services first reported a position in Standard BioTools in Q4 2025 and held it in 1 quarter.
  • Keating Financial Advisory Services's Standard BioTools position peaked at $515 in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.